Recently, CAR T-cell therapy was successfully administered to patients with refractory SLE using CD19-targeted T cells.8 Additionally, regulatory T (Treg) and natural killer (NK) cell therapies for SLE have been explored, although research data and clinical experience are still limited. This evidence concerns the gene CD19 and systemic lupus erythematosus.